Oncotarget

Research Papers:

Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1

Byong-Ki Cha, Young-Suk Kim, Ki-Eun Hwang, Kyung-Hwa Cho, Seon-Hee Oh, Byoung-Ryun Kim, Hong-Young Jun, Kwon-Ha Yoon, Eun-Taik Jeong _ and Hak-Ryul Kim

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:57213-57227. https://doi.org/10.18632/oncotarget.11127

Metrics: PDF 987 views  |   HTML 1588 views  |   ?  


Abstract

Byong-Ki Cha1,*, Young-Suk Kim2,*, Ki-Eun Hwang2, Kyung-Hwa Cho2, Seon-Hee Oh3, Byoung-Ryun Kim4, Hong-Young Jun5, Kwon-Ha Yoon6, Eun-Taik Jeong2, Hak-Ryul Kim2

1Department of Thoracic and Cardiovascular Surgery, Chonbuk National University Medical School, Jeonbuk, Korea

2Departments of Internal Medicine, Institute of Wonkwang Medical Science, Wonkwang University, School of Medicine 344-2 shinyong-dong Iksan, Jeonbuk, Korea

3Department of Premedicine, School of Medicine, Chosun University, Gwangju, Korea

4Department of Obstetrics & Gynecology, Wonkwang University, School of Medicine, Iksan, Jeonbuk, Korea

5Imaging Science Research Center, Wonkwang University, School of Medicine, Iksan, Jeonbuk, Korea

6Departments of Radiology, Wonkwang University, School of Medicine, Iksan, Jeonbuk, Korea

*These authors have contributed equally to this work

Correspondence to:

Hak-Ryul Kim, email: kshryj@wku.ac.kr

Keywords: celecoxib, sulindac, EMT, SIRT1, lung cancer

Received: December 16, 2015    Accepted: July 26, 2016    Published: August 09, 2016

ABSTRACT

The non-steroidal anti-inflammatory drugs (NSAIDs) celecoxib and sulindac have been reported to suppress lung cancer migration and invasion. The class III deacetylase sirtuin 1 (SIRT1) possesses both pro- and anticarcinogenic properties. However, its role in inhibition of lung cancer cell epithelial-mesenchymal transition (EMT) by NSAIDs is not clearly known. We attempted to investigate the potential use of NSAIDs as inhibitors of TGF-β1-induced EMT in A549 cells, and the underlying mechanisms of suppression of lung cancer migration and invasion by celecoxib and sulindac. We demonstrated that celecoxib and sulindac were effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors. Moreover, celecoxib and sulindac could inhibit TGF-β1-enhanced migration and invasion of A549 cells. SIRT1 downregulation enhanced the reversal of TGF-β1-induced EMT by celecoxib or sulindac. In contrast, SIRT1 upregulation promoted TGF-β1-induced EMT. Taken together, these results indicate that celecoxib and sulindac can inhibit TGF-β1-induced EMT and suppress lung cancer cell migration and invasion via downregulation of SIRT1. Our findings implicate overexpressed SIRT1 as a potential therapeutic target to reverse TGF-β1-induced EMT and to prevent lung cancer cell migration and invasion.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11127